Dr Metersky provides his closing thoughts, highlighting key points of emphasis surrounding bronchiectasis care and the future of its treatment landscape. This is a video synopsis/summary of an ...
One woman's journey from an unexpected diagnosis to learning how to manage a chronic, progressive lung disease.
Panelists discuss how evaluating potential causes of bronchiectasis is important despite many cases being idiopathic, as identifying treatable traits can lead to specific interventions, such as CFTR ...
Is a Serious, Progressive Lung Disease That Can Lead to Permanent Lung Damage[i] — BRINSUPRI Is a First-in-Disease, First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation — BRINSUPRI Was ...
—Brensocatib Would be the First and Only Available Treatment for Bronchiectasis and First DPP1 Inhibitor, if Approved— BRIDGEWATER, N.J., Feb. 6, 2025 /PRNewswire/ -- Insmed Incorporated (INSM), a ...
— If Approved, BRINSUPRI Would Be the First and Only Treatment in the European Union for Non-Cystic Fibrosis Bronchiectasis (NCFB) and the First-in-Class DPPI Inhibitor Targeting Neutrophilic ...
Pharmaceutical Technology on MSN
Insmed receives EC approval for Brinsupri to treat NCFB
"Insmed receives EC approval for Brinsupri to treat NCFB" was originally created and published by Pharmaceutical Technology, ...
Zacks Investment Research on MSN
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
Insmed INSM announced that the European Commission has approved Brinsupri (brensocatib) for the treatment of non-cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback